These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 37767626)
1. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654 [TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
4. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer. Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S Oncol Ther; 2024 Jun; 12(2):329-343. PubMed ID: 38502426 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302 [TBL] [Abstract][Full Text] [Related]
6. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. Zhao S; Zhang Z; Zhan J; Zhao X; Chen X; Xiao L; Wu K; Ma Y; Li M; Yang Y; Fang W; Zhao H; Zhang L BMC Med; 2021 Oct; 19(1):223. PubMed ID: 34592968 [TBL] [Abstract][Full Text] [Related]
7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917 [TBL] [Abstract][Full Text] [Related]
8. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529 [TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L. Uemura T; Kenmotsu H; Hazama D; Teraoka S; Kobe H; Azuma K; Yamaguchi T; Masuda T; Yokoyama T; Otsubo K; Haratani K; Hayakawa D; Oki M; Takemoto S; Ozaki T; Akashi Y; Hata A; Hashimoto H; Yamamoto N; Nakagawa K Cancer Med; 2023 Dec; 12(23):21097-21110. PubMed ID: 37948122 [TBL] [Abstract][Full Text] [Related]
10. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297 [TBL] [Abstract][Full Text] [Related]
11. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization. Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective. Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea. Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220 [TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885 [TBL] [Abstract][Full Text] [Related]
18. Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma. Muthusamy B; Raskina K; Lofgren KT; Li G; Tolba K; Schwed K; Castellanos E; Huang RSP; Oxnard GR; Schrock AB; Pennell N J Thorac Oncol; 2023 Apr; 18(4):476-486. PubMed ID: 36494074 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569 [TBL] [Abstract][Full Text] [Related]
20. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]